Reuters logo
BRIEF-Durect and Sandoz signs a $293 mln development and commercialization agreement for Posimir
2017年5月8日 / 上午11点17分 / 5 个月前

BRIEF-Durect and Sandoz signs a $293 mln development and commercialization agreement for Posimir

May 8 (Reuters) - Durect Corp:

* Durect and Sandoz have signed a $293 million development and commercialization agreement for Posimir (saber-bupivacaine) covering the United States

* Durect Corp - Durect will remain responsible for completion of ongoing persist phase 3 clinical trial for posimir as well as fda interactions through approval Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below